18F-mFBG PET Imaging in the Evaluation of Neuroblastoma
Condition(s) studied
Investigational drug(s) / intervention(s)
18F-MFBG: Patients with neuroblastoma malignancies receive 5.55 MBq/kg of 18F-MFBG intravenously followed by PET/CT or PET/MR after 60min of injection.
Study summary
The aim of this study is to evaluate the diagnostic performance and tumor burden of 18F-metafluorobenzylguanidine (18F-MFBG) positron emission tomography (PET) in patients with neuroblastoma.
Eligibility
Primary outcome measure(s)
- Diagnostic efficacy — through study completion, an average of 1.5 year
Sensitivity, specificity, positive and negative predictive value of 18F-mFBG PET/CT and PET/MR Imaging in neuroblastoma
Trial sites (1)
| Facility | City | Region | Status |
|---|---|---|---|
| The First Affiliated Hospital of Zhejiang University School of Medicine | Hangzhou | Zhejiang | Recruiting |
More First Affiliated Hospital of Zhejiang University trials in China
Other trials for the same condition
This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.
View NCT06852807 on ClinicalTrials.gov ↗ ← All trials in China